Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04630093 · ClinicalTrials.gov registry record · NA

Pilot of Preemptive Pharmacogenetics in Medically Underserved Patients

A NA study, sponsored by University of Florida.

Completed
Registry status
NA
Development phase
100
Enrollment target

NCT04630093 is a NA study that has completed, run by University of Florida. The registered enrollment target is 100 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04630093, a NA study, has completed, sponsored by University of Florida.

COMPLETED
Registry status
NA
Development phase
100 participants
Enrollment target

Study Summary

This is a pragmatic clinical trial of 100 patients who self-identify as black or Latino. Patients with active prescriptions for at least 3 medications and a medication change within the past 6-months will be recruited from the University of Florida (UF) Health primary care clinics for panel-based pharmacogenetic testing. Participants will be followed for 6 months and will undergo assessments with the Treatment Satisfaction Questionnaire for Medication (TSQM) three times (baseline visit, 3-month visit, and 6-month visit post pharmacogenetic testing). In addition, data on effectiveness outcomes and socioeconomic measures will be collected via the electronic health record (EHR) and patient report. Participation is expected to last approximately 6 months and the study will be open for approximately 12-14 months.

Interventions

  • DIAGNOSTIC_TEST Panel-based pharmacogenetic genotyping

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2021-05-13
Est. Completion 2022-06-22
Phase NA

Sponsor

University of Florida

1,106 total trials

What the Registry Record Tells You About NCT04630093

The ClinicalTrials.gov registry entry for NCT04630093 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Panel-based pharmacogenetic genotyping is the first listed.

NCT04630093 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04630093 about?

NCT04630093 is a clinical study titled "Pilot of Preemptive Pharmacogenetics in Medically Underserved Patients". This is a pragmatic clinical trial of 100 patients who self-identify as black or Latino. Patients with active prescriptions for at least 3 medications and a medication change within the past 6-months will be recruited from the University of Florida (UF) Health primary care clinics for panel-based ph...

What is the current status of trial NCT04630093?

This trial is currently completed. It is a NA study. The enrollment target is 100 participants. The study started on 2021-05-13. Estimated completion is 2022-06-22.

What interventions are being tested in trial NCT04630093?

The interventions under investigation include: Panel-based pharmacogenetic genotyping (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT04630093?

This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.